Dual protease activated peptides for specific targeting
Dual protease activated peptides for specific targeting
批准号:
10680341
负责人:
Ethel Naa Odey Tackie-Yarboi
金额:
$6.91万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2025-06-30
关键词:
AddressAmino AcidsBacterial InfectionsBee VenomsBindingBiological AssayCASP3 geneCalorimetryCell LineCell membraneCellsCellular AssayCellular MembraneChargeCircular DichroismCouplingCytolysisCytotoxinDerivation procedureDiagnosticDiscriminationDiseaseDrug Delivery SystemsErythrocytesExtravasationFluorescenceFutureHigh Pressure Liquid ChromatographyIn SituIn VitroIncubatedInfectionInvestmentsKineticsLabelLinkLiteratureLocationMalignant NeoplasmsMammalian CellMasksMembraneMetabolicMethodsMolecular ConformationMonitorNerve DegenerationParentsPenetrationPeptide HydrolasesPeptidesPharmaceutical PreparationsPlayProdrugsPropertyProteinsProteolysisResearchRoleSerumSideSolid NeoplasmSpecificitySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStructureSystemTechniquesTestingTherapeuticToxinTrainingVesicleWI 38 cellWhole Bloodalpha helixanti-canceranti-cancer therapeuticantimicrobialantimicrobial peptideaqueousbiophysical analysisbiophysical techniquescancer biomarkerscytotoxiccytotoxicitydesigndrug marketexpectationfibroblast-activating factorimprovedmicrobialoverexpressionpeptide drugpeptide hormonephysical propertypreventprototyperesponseside effectskillssmall moleculetumorunilamellar vesicle
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Here we develop a platform for protease-activated peptide prodrugs. We initially focus the effort on
antimicrobial peptides (AMP), which have a broad spectrum of cell-penetrating, antimicrobial and cytotoxic
activities. However, they have multiple limitations, including off-target cytotoxicity and proteolytic instability. To
circumvent these unwanted effects, linear protease-activated prodrugs have been employed. Although effective
at enhancing the activity of the active payload, it does not adequately address the side effects stated above. To
mitigate the side effects of the traditional protease-activated prodrug approach, the proposed research strategy
herein seeks to design a branched protease-activated prodrug by coupling a cleavable linker to the sidechains
of amino acid residue that significantly impacts antimicrobial peptide activity. As a proof-of-concept, bombolitin
(an AMP that is cytotoxic to mammalian cells) will be used as the payload, masked with caspase-3 and fibroblast
activation protein (cancer biomarkers) substrate-specific linkers. By modifying the sidechains of Lys, Ser, Thr,
and Tyr with these linkers, we hypothesize that the physicochemical properties of bombolitin will be significantly
altered, thus reducing peptide-membrane interaction until activation. In this research, we propose to 1) design
and synthesize single and double-branched protease-activated prodrugs cleaved in the presence of either
caspase-3 and/or fibroblast activation protein to yield the active peptide, 2) confirm caspase-3 and fibroblast
activation protein cleavage of linker from prodrugs by performing in vitro enzymatic assays and biophysical
analysis, and 3) perform cell-based assays to validate prodrug cleavage, target specificity, activity enhancement,
and reduction of off-target effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金